Method for detecting pazopanib drug concentration in human plasma by LC-MS/MS (liquid chromatography-mass spectrometry/mass spectrometry)
Patent Information
- Authority / Receiving Office
- CN Β· China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH
- Publication Date
- 2021-01-29
- Estimated Expiration
- Not applicable Β· inactive patent
Smart Images

Figure 1 
Figure 2 
Figure 3
Abstract
Description
technical field
[0001] The invention relates to a method for detecting drug concentration, and belongs to the technical field of drug concentration analysis, in particular to a method for detecting the drug concentration of pazopanib in human plasma by combining LC-MS / MS. Background technique
[0002] Renal cell carcinoma (RCC) is one of the most common malignant tumors of the urinary system, accounting for more than 80% of renal malignant tumors. The onset of RCC is hidden, and more than 30% of patients have been diagnosed with metastasis, and RCC is not sensitive enough to radiotherapy and chemotherapy. In the past 10 years, with the development of targeted drugs, the treatment of metastatic RCC has entered the era of targeted therapy.
[0003] Pazopanib hydrochloride was developed by GlaxoSmithKline and was approved by the U.S. Food and Drug Administration (FDA) in October 2009 for listing in the U.S. under the trade name Votrient for the treatment of advanced renal cell...